Apnimed posts Phase 2 MARIPOSA results showing AD109 cut AHI4 versus placebo

Apnimed's week centered on results posted for its completed Phase 2 obstructive sleep apnea study.

• The trial, "Parallel Arm Trial of AD109 and AD504 In Patients With OSA" (MARIPOSA, NCT05071612), enrolled 294 participants and was a phase 2 randomized double-blind placebo-controlled parallel-arm dose finding study.¹ The study was completed with primary completion on 2022-07-20, and results were first posted on 2026-08-12.
• Combined AD109 arms showed a change in Apnea-Hypopnea Index (AHI4) from baseline of -7.38 events/hr, compared with -0.21 for placebo, with the mixed models analysis reporting p<0.0001.¹
• No serious adverse events were reported in any arm, including 0 of 41 in the AD109 75/5mg arm, 0 of 42 in the AD109 75/2.5mg arm, 0 of 43 in the AD504 75/100mg arm, 0 of 40 in the AD504 75/50mg arm, 0 of 63 in the Atomoxetine 75mg arm, and 0 of 63 in the placebo arm.¹